Literature DB >> 34389240

Extracellular matrix-based cancer targeting.

Nikos K Karamanos1, Zoi Piperigkou2, Alberto Passi3, Martin Götte4, Patricia Rousselle5, Israel Vlodavsky6.   

Abstract

Tumor extracellular matrix (ECM) operates in a coordinated mode with cancer and stroma cells to evoke the multistep process of metastatic potential. The remodeled tumor-associated matrix provides a point for direct or complementary therapeutic targeting. Here, we cover and critically address the importance of ECM networks and their macromolecules in cancer. We focus on the roles of key structural and functional ECM components, and their degradation enzymes and extracellular vesicles, aiming at improving our understanding of the mechanisms contributing to tumor initiation, growth, and dissemination, and discuss potential new approaches for ECM-based therapeutic targeting and diagnosis.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer; collagen; extracellular matrix; hyaluronan; matrix remodeling enzymes; proteoglycans

Mesh:

Year:  2021        PMID: 34389240     DOI: 10.1016/j.molmed.2021.07.009

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  14 in total

1.  ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo.

Authors:  Zoi Piperigkou; Anastasios Koutsandreas; Marco Franchi; Vasiliki Zolota; Dimitrios Kletsas; Alberto Passi; Nikos K Karamanos
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

2.  MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.

Authors:  Congjun Wang; Ye Wang; Zhao Fu; Weijia Huang; Zhu Yu; Jiancheng Wang; Kaitian Zheng; Siwen Zhang; Shen Li; Junqiang Chen
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

3.  Collagen Linearization within Tumors.

Authors:  Craig E Barcus; Gregory D Longmore
Journal:  Cancer Res       Date:  2021-11-15       Impact factor: 13.312

4.  Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling.

Authors:  Yanmiao Huo; Jian Yang; Jiahao Zheng; Dapeng Xu; Minwei Yang; Lingye Tao; Hongfei Yao; Xueliang Fu; Jianyu Yang; Dejun Liu; Rong Hua; Junfeng Zhang; Yongwei Sun; Lipeng Hu; Wei Liu
Journal:  Cell Prolif       Date:  2022-04-29       Impact factor: 8.755

5.  Matrix Effectors and Cancer.

Authors:  Zoi Piperigkou; Nikos K Karamanos
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

Review 6.  Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression.

Authors:  Stephan Niland; Andrea Ximena Riscanevo; Johannes Andreas Eble
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

Review 7.  The Proteolysis of ECM in Intervertebral Disc Degeneration.

Authors:  Huaizhen Liang; Rongjing Luo; Gaocai Li; Weifeng Zhang; Yu Song; Cao Yang
Journal:  Int J Mol Sci       Date:  2022-02-02       Impact factor: 5.923

8.  Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  Neel I Nissen; Astrid Z Johansen; Inna Chen; Julia S Johansen; Rasmus S Pedersen; Carsten P Hansen; Morten A Karsdal; Nicholas Willumsen
Journal:  Cancers (Basel)       Date:  2022-02-06       Impact factor: 6.639

9.  Overexpression of the Hsa21 Transcription Factor RUNX1 Modulates the Extracellular Matrix in Trisomy 21 Cells.

Authors:  Nunzia Mollo; Miriam Aurilia; Roberta Scognamiglio; Lucrezia Zerillo; Rita Cicatiello; Ferdinando Bonfiglio; Pasqualina Pagano; Simona Paladino; Anna Conti; Lucio Nitsch; Antonella Izzo
Journal:  Front Genet       Date:  2022-03-10       Impact factor: 4.599

10.  The IFN-γ-related long non-coding RNA signature predicts prognosis and indicates immune microenvironment infiltration in uterine corpus endometrial carcinoma.

Authors:  Chunyan Gu; Chen Lin; Zheng Zhu; Li Hu; Fengxu Wang; Xuehai Wang; Junpu Ruan; Xinyuan Zhao; Sen Huang
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.